These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 23564273)

  • 61. Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder.
    Heal DJ; Gosden J; Smith SL
    Adv Pharmacol; 2024; 99():251-286. PubMed ID: 38467483
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
    Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
    J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.
    Weisler RH; Babcock T; Adeyi B; Brams M
    Postgrad Med; 2014 Sep; 126(5):31-41. PubMed ID: 25295648
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.
    Castells X; Blanco-Silvente L; Cunill R
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD007813. PubMed ID: 30091808
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse.
    Jasinski DR; Krishnan S
    J Psychopharmacol; 2009 Jun; 23(4):419-27. PubMed ID: 19329547
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
    Lopez FA; Ginsberg LD; Arnold V
    Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of lisdexamfetamine dimesylate treatment for ADHD on growth.
    Faraone SV; Spencer TJ; Kollins SH; Glatt SJ
    J Am Acad Child Adolesc Psychiatry; 2010 Jan; 49(1):24-32. PubMed ID: 20215923
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States.
    Zhou Z; Zhou ZY; Kelkar SS; Sikirica V; Xie J; Grebla R
    Curr Med Res Opin; 2018 Apr; 34(4):585-592. PubMed ID: 29186993
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.
    Findling RL; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; DeLeon A; Ginsberg LD
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):28-35. PubMed ID: 23410139
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.
    Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu EQ; Erder MH
    J Med Econ; 2013 Jul; 16(7):962-75. PubMed ID: 23621503
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Krishnan S; McGough JJ
    CNS Spectr; 2008 Jul; 13(7):614-20. PubMed ID: 18622366
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].
    Häge A; Banaschewski T; Dittmann RW
    Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Participant-perceived quality of life in a long-term, open-label trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Childress AC; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Findling RL
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):210-7. PubMed ID: 24815910
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Lisdexamfetamine: A Review in ADHD in Adults.
    Frampton JE
    CNS Drugs; 2016 Apr; 30(4):343-54. PubMed ID: 27048350
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
    Brown TE; Brams M; Gao J; Gasior M; Childress A
    Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Population pharmacokinetic and exposure-response analyses of d-amphetamine after administration of lisdexamfetamine dimesylate in Japanese pediatric ADHD patients.
    Tsuda Y; Matsuo Y; Matsumoto S; Wajima T
    Drug Metab Pharmacokinet; 2020 Dec; 35(6):548-554. PubMed ID: 33082099
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A new amphetamine oral suspension (Adzenys ER) for ADHD.
    Med Lett Drugs Ther; 2018 Jun; 60(1549):e106-e108. PubMed ID: 29913476
    [No Abstract]   [Full Text] [Related]  

  • 78. ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years.
    López FA; Childress A; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser RA; Shepski J; Arnold V
    J Atten Disord; 2017 Jan; 21(1):52-61. PubMed ID: 23407278
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management.
    O'Connor L; Carbone S; Gobbo A; Gamble H; Faraone SV
    Expert Rev Clin Pharmacol; 2023; 16(9):799-812. PubMed ID: 37587841
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD.
    Dupaul GJ; Weyandt LL; Rossi JS; Vilardo BA; O'Dell SM; Carson KM; Verdi G; Swentosky A
    J Atten Disord; 2012 Apr; 16(3):202-20. PubMed ID: 22166471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.